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COMPARATIVE EFFECTIVENESS RESEARCH
IN THE UNITED STATES*
Sonsy Pulikotil Rajan**

INTRODUCTION
The one hundred and eleventh Congress acted in early 2009 to expand the funding
for Comparative Effectiveness Research in the midst of an economic crisis and a failing health
care system ("CER"). On February 17, 2009, President Barack Obama signed the American
Recovery and Reinvestment Act of 2009 ("ARRA"). The Act provided $1.1 billion for conducting comparative effectiveness research of drugs, medical treatments, surgical procedures
and other treatments for various conditions.' This funding was provided to the National Institutes of Health ("NIH"),2 the Agency for Health Care Research and Quality ("AHRQ"), 3 and
the Secretary of Human Health and Services ("HHS").4 The goal of this funding is to "conduct, support, or synthesize research that compares the clinical outcomes, effectiveness, and
appropriateness of items, services and procedures that are used to prevent, diagnose or treat
diseases, disorders and other health conditions".5 As the congressional debate on health care
reform grew during the first year of Obama administration and the first session of the one
hundred and eleventh Congress, so too has the specific debate regarding CER. Opponents
claim that CER represents governmental intrusion into health decisions that should be made in
private, between the patient and the physician, and that it will lead to government rationing of
health care. Proponents claim that with the advent of new technologies, new drugs and various
* This article was presented as a poster in the health policy conference 'New Directions in American Health
Care: Innovations from Home and Abroad' that occurred in Hofstra University during March 2010.
** J.D. Candidate, 2011, Hofstra University of Law; M.S., Biomedical Engineering; Louisiana Tech University,
2004; B.E., Electronics and Communication Engineering, Bharathiar University, 2001. I thank the Lord
Almighty for His abounding grace and mercy in my life thus far. I thank the entire staff of the Journal,
particularly Matt Amon and Omer Shahid, for their support. I thank Prof. Alan Jakimo, Hofstra University
School of Law and Dr. Beje Thomas, M.D., Medical University of South Carolina for their guidance in writing
this article. I express my sincere gratitude to my husband, Rinu Rajan and my daughters Abigail and Hannah
Rajan for their love and support. Finally, I thank my parents and siblings for being there for me always. This
article is dedicated with love to my daughters-Abigail and Hannah Rajan, for you are my inspiration.
I The American Recovery and Reinvestment Act of 2009 (ARRA), Pub. L. No 111-5, 123 Stat. 115, 111th
Cong., Ist sess. (2009).
2 "The National Institutes of Health (NIH), a part of the U.S. Department of Health and Human Services, is the
primary Federal agency for conducting and supporting medical research".
3 See Agency for Healthcare Research and Quality, available at www.ahrq.gov, [hereinafter "AHRQ"]. "The
Agency for Healthcare Research and Quality's (AHRQ) mission is to improve the quality, safety, efficiency,
and effectiveness of health care for all Americans. Information from AHRQ's research helps people make more
informed decisions and improve the quality of health care services. AHRQ was formerly known as the Agency
for Health Care Policy and Research"
4 "The Department of Health and Human Services (HHS) is the United States government's principal agency
for protecting the health of all Americans and providing essential human services, especially for those who are
least able to help themselves"); see also, American Recovery and Reinvestment Act of 2009 (ARRA), Pub. L.
No. 111-5, 123 Stat. 115 (2009) [hereinafter "ARRA"].
5 The American Recovery and Reinvestment Act of 2009 (ARRA), Pub. L. No. 111-5, 123 Stat. 115, 11Ith
Cong., Ist sess. (2009).
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other treatments for disease conditions, it is imperative that we know "what works best in
medicine". 6
Historically, the practice of medicine has been a mix of science and art.' A significant portion of the clinical practice of medicine, which is embedded in the science component,
has been based on the knowledge and experience of physicians derived from education and
training.8 In order to reach an optimal mix of science and art, there should be a harnessing of
available knowledge on treatment methods for particular disease condition. The harnessed
knowledge and the findings must then be integrated into the everyday practice of medicine.
More importantly, the integration process must emphasize the balance between the expected
benefits verses the costs associated with treatments. 9 A gap in integration deprives patients of
the opportunity of receiving the most efficacious treatment. It also affects the value associated
with treatment options, which is dictated by the cost of the treatment and the benefits derived
from them. This lack in value of health care received, in turn, will affect the affordability of
health care for society as a whole.' 0 Therefore, creating avenues that enable development,
dissemination and incorporation of available knowledge on any disease condition will eventually provide high quality health care in a cost effective manner.' 1
This note will discuss the potential importance of CER to the US health care system
and what we must and must not learn from other countries, particularly the United Kingdom,
that have implemented CER systems for allocating government funds to health care. Part I
will provide an overview on comparative effectiveness research and the need for CER in the
US health care system. Part II will explain United Kingdom's CER system, called "National
Institute for Clinical Excellence, also called "NICE", and how this system applies to the anticancer EGFR blocker Certuximab (brand name Erbitux) and anticancer tyrosine kinase inhibitor Sunitinib (brand name Sutent). Part III will briefly describe the history of CER in the US.
Part IV will discuss the obstacles and policy implications that the US might face in implementing CER. Part V will propose several regulatory approaches for implementing CER in the
US and finally part VI will provide recent developments in the regulatory spending on CER
funded by the American Reinvestment and Recovery Act of 2009.

6 Nallamothu BK, Bradley EH, & Krumholz HM, Time to Treatment In Primary Percutaneous Coronary

Intervention, 357 NEW Eng.J. Med. 1631 (2007). "Early administration of reperfusion therapy improves
survival in patients with ST-elevation myocardial infarction by reestablishing coronary blood flow within the
occluded infarct-related artery. Primary percutaneous coronary intervention (PCI) is superior to fibrinolytic
therapy when performed rapidly by expert teams, but its effectiveness may be limited by delays in delivery.
Recent national efforts are drawing attention to the importance of door-to-balloon time as a key indicator of
quality of care for patients with ST-elevation myocardial infarction who are treated with primary PCI".
7 See Bernadine Healy, Medicine, the Art, US NEWS AND WORLD REPORT (July. 15, 2007), available at http://
health.usnews.com/usnews/health/articles/070715/23healy.htm (last visited Nov 13, 2009).
8 See id.
9 Kevin G. Volpp & Anup Das, Comparative Effectiveness-Thinking beyond Medication A versus Medication
B, 361 NEw ENG.J. MED.331-336 (July 2009).
10 See id. at 331.
1t Aanand D. Naik & Laura A. Petersen, The Neglected Purpose of Comparative-Effectiveness Research, 360
New ENG.J. MED.1929 -1931 (2009).
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I.

WHAT IS COMPARATIVE EFFECTIVENESS RESEARCH (CER)?

Generally, a traditional clinical trial of any given drug compares the safety and efficacy of a drug with that of a placebo. 12 They do not provide data that compares the efficiency
of the drug with two or more existing treatment options. Comparative effectiveness research
addresses this by comparing a specific treatment option with one or more other drug, medical
device, surgery regimen or other treatment option available for a particular disease condition.
The information is tailored specifically to patient group or a subgroup. 13
If one medical provider could diagnose and treat a condition for $2000 while another
medical provider diagnoses and treats the same condition for $4000, there is evidently a value
gap in the cost-benefit analysis. CER will explore the value benefits associated with each
treatment compared to its respective relative treatment option. With the information on the
relative benefit of treatments, health care providers can curtail cost associated with treatments.
CER will also enable the provider to choose treatment options that are clinically effective as
well as cost effective. 14 On the payor-side, the insurance companies can design value based
insurance designs which compare the value gained by the patient with the cost associated with
it. On the patient side, CER will provide a summary of efficacy, safety, and post market
surveillance of different drugs used to treat the same disease condition and will determine
value associated with each option. 15 Based on the information from CER, patients can evaluate their treatment options and compare the cost of treatment under different providers.
One of the well-known clinical effectiveness research studies is the Diabetes Prevention Program sponsored by the Diabetes Prevention Program Research Group under the supervision of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and
NIH.' 6 The program compared lifestyle intervention to Metforminl 7 therapy in the prevention
of diabetes.1 " The study showed that intensive lifestyle therapy was more effective than
Metformin therapy. Lifestyle intervention reduced the incidence of diabetes by 58percent
compared to placebo while the Metformin therapy reduced the incidence of diabetes by 3 1percent compared to placebo.19
In the present US health care system there is little information regarding which of
the two treatments works more effectively on specific patients or whether the cost associated

Asbjorn Hrobjartsson & Peter C. Gotzsche, Is the Placebo Powerless?- An Analysis of Clinical Trials
ComparingPlacebo with No Treatment, 344 NEw ENG.J. MED.1594-1602 (2001).
13 Kalipso Chalkidou & Gerard Anderson, ComparativeEffectiveness Research: InternationalExperiences and
12

Implicationsfor the United States (2009), ACADEMY OF HEALTH, (July 2009), http://www.academyhealth.org/
.. /CERInternationalExperience_.09percent20(3).pdf.
14 Id.
' Id.
16 See Diabetes PreventionProgram, NATIONAL DIABETEs INFORMATION CLEARING HOUSE (NDIC), available

at http://diabetes.niddk.nih.gov/dm/pubs/preventionprogram/#info

(last visited Oct.10, 2010) [hereinafter

"NDIC"I.
17 See Metformin, http://www.mayoclinic.com/health/drug-information/DR60t533

(last visited Nov.13, 2009).

18See William C. Knowler, Dr.P.H., Elizabeth Barrett-Connor, Sarah E. Fowler, Richard F. Hamman, John M.
Lachin, Elizabeth A. Walker, & David M. Nathan, Reduction in the Incidence of Type 2 Diabetes with Lifestyle
Intervention or Metformin, 346 NEw ENG.J. MED.393-403 (2002).
19 See id. at 403
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with each treatment renders value. 20 First, the fee-for-treatment system favors the medical
providers. As a result, even if a treatment shows little benefit or value, providers and patients
tend to opt expensive treatments as long as the payment exceeds costs. 2 1 Second, the fee-for-

treatment system results in medical providers making decisions based on their judgments,
experience and other evidence associated with their practice of medicine. Less than half of the
medical decisions made in the US are based on evidence of the effectiveness of the
treatment. 22
The Problem
Why Do We Need CER In The United States
The US health care system is in the midst of a tumult. The US spends twice per
capita for health care compared to many industrialized countries. 23 In 2007, US spending on
healthcare was estimated to be $2.3 trillion or $7600 per person. 24 After continued growth in
spending and a change in the presidential administrations, the issue of health care has again
reached the national stage with great vigor. Concerns include an increase in health care costs,
decrease in the value gained, an increase in number of the people without health insurance,
rise in the baby boomer generation, rise in medical litigation and people paying more to maintain their medical insurance. 25
It is estimated that as of 2007, twenty-five million insured people from ages 19-64
are underinsured. 26 Moreover, 42 percent of American adults are underinsured or uninsured. 27
Most Americans are not covered for all medical expenses or conditions. Medical insurance
might not cover certain conditions or certain diseases. 2 8 Even though families are insured, the
high cost of out-of-pocket expenses causes financial burdens on working class American families. 29 According to the Bureau of Economic Analysis, in 2007, an average American family
20 Peter R. Orszag, & Philip Ellis, Addressing Rising Health Care Costs -A View from the Congressional
Budget Office, 357 NEw ENG.J. MED.1885 -1887 (Nov 2007), available at http://content.nejm.org/cgi/content/
full/357/19/1885, (last visited Nov. 1, 2009) [hereinafter "Orszag"].
21 See id.
22 Id.

23 Cathy Schoen, Osborn R, Doty MM, Bishop M, Peugh J, & Murukutla N, Toward Higher - Performance
Health Systems: Adults' Health Care Experiences in Seven Countries, 27 HEALTH AFFARs 717 -734 (2007);
See also Knauf, F & Aronson, P. S, ESRD as a Window into America's Cost Crisis in Health Care, 20 J. AM.
Soc. NEPHROL 2093-2097 (2009), available at http://jasn.asnjoumalswww.asn-online.org/content/20/10/2093.
fullpolicy-and-public affairs/docs/ESRDpercent20aspercent20apercent20Windowpercent20intopercent20
-eO
America'spercent20Costpercent2OCrisispercent2Oinpercent2OHealthpercent20Care.pdf+html?sid=69a3d641
97-4aa7-9bcd-f41e0f56ac2a (last visited Mar. 8, 2010).
24 Poisal JA, Truffer C, Smith S, et al, Health spending projections through 2016: modest changes obscure
part D's impact, 26 HEALTH AFFAiRS 242 -53 (2007).
25 Thomas L. Creer, Will healthcare reform actually occur in the US?, 5 CHRoNic ILLNEss 134 -141 (2009),
available at http://chi.sagepub.com/cgi/content/abstract/5/2/134 (last visited Nov. 29, 2009).
26 Cathy Schoen, Sara R. Collins, Jennifer L. Kriss & Michelle M. Doty, How Many Are Underinsured?
Trends Among U.S. Adults, 2003 And 2007, 27 HEALTH AFFAms 298-309 (2008), available at http://www.
commonwealthfund.org/Content/Publications/In -the-Literature/2008/Jun/How -Many -Are-Underinsured - Trends -Among -U-S-Adults -2003 -and-2007.aspx (last visited Nov 13, 2009).
27 See id. at 300.
28 id.
29 See id. at 302.
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spent about 16.7 percent of their disposable income for medical care costs compared to other
costs such as food (14.4%), housing (13.1%), and clothing and shoes (3.6%),3o
Rising health care cost has adverse affect on people with chronic conditions. A study
conducted by the Agency of Health Care Research and Quality based on Medical Expenditure
Panel Survey (MEPS) showed a prevalence of self reported chronic conditions in people of
old age, mid life and earlier old age. This increase signifies a substantial out-of-pocket expense. 31 Additionally, most people are reported to have more than one chronic condition. 3 2
Families with members who have chronic conditions are 2.6 times more likely to spend more
than $1000 for their medical care costs. The burdens imposed by chronic conditions tend to
prolong for many years. 33 Additionally, uninsured chronically ill patients had the highest
medical care spending but were five times less likely to see a physician in a year. This signifies that chronically ill patients utilize more resources but receive limited benefits when compared to the rest of the patient population. 34
It is estimated that at the present rate, health care spending will consistently outpace
the gross domestic product (GDP) growth by 20 percent by 2015, which would equal the
present share of the entire federal budget.3 5 By 2015, the baby boomers will qualify for the
Medicare benefits. 36 By 2030, the Americans over the age of 65 will comprise one fifth of the
population, and will consume 50 percent of the health care spending. 37 The cost of prescription drugs has been on the rise during the past decade. Many blockbuster drugs that treat a rare
disease condition represent a significant amount of cost to the patients. For Example, a blockbuster drug called Cerezyme (an analogue of the human enzyme 8 -glucocerebrosidase), 8
which treats a rare and fatal disease called Gaucher disease costs more than $300,000 per
year.39 The total estimated sale of Cerezyme is $1.1 billion, whereas the population affected
by the disease around the world is only 5000 patients.40 The private insurance companies
3o Karen Davis, Slowing the Growth of Health Care Costs-Learningfrom InternationalExperience, 359 NEW
ENG.J. MED. 1751 -1755 (October 2008).

31 Kathryn Anne Paez, Lan Zhao & Wenke Hwang, Rising Out Of Pocket Spending For Chronic Conditions:A
Ten Year Trend, 28 HEALTH AFFAIRs 15-25 (2009).

3 See id.
3 Wenke Hwang, Wendy Weller, Henry Ireys & Gerard Anderson, Out-Of-Pocket Medical Spending For Care
Of Chronic Conditions, 20 HEALTH AFFAIRs 267-277 (November/December 2001), available at http://
content.healthaffairs.org/cgi/content/full/20/6/26 7?ijkey=540ealb8532583ad3574edd6bd42ecea994b4fbf (last
visited Nov.13, 2009).
34 See id.
3 See Cathy Schoen, supra note 23, at 718; see also Orszag, supra note 20.
36 U.S. Healthcare Costs, 2006, THE HENRY J. KAISER FAMILY FOUNDATION, available at www.kaiseredu.org
(last visited Nov 13, 2009).
3 Robert J. Samuelson, Rxfor Health care Pain, NEWSWEEK, Dec.17.2007

3 See Cerezyme, CEREZYME.COM, available at http://www.cerezyme.com/home/default.asp (last visited Nov
30, 2009) [hereinafter "Cerezyme]. Cerezyme is manufactured by Genzyme. It is "an anlogue of 8Glucocerebrosidase produced by recombinant DNA technology. B - Glucocerebrosidase (B-D-glucosyl -Nacylsphingosine glucohydrolase) is a lysosomal glycoprotein enzyme,which catalyzes the hydrolysis of the
glycolipid glucocerebroside to glucose and ceramide. Cerezyme (imiglucerase for injection) is indicated for
long-term enzyme replacement therapy for pediatric and adult patients with a confirmed diagnosis of Type 1
Gaucher disease that results in one or more of the following conditions: anemia, thrombocytopenia, bone
disease, hepatomegaly or splenomegaly".
3 When a drug costs $300,000, N. Y. TIMEs, Mar. 23. 2008, available at www.nytimes.com, www.
plosmedicine.org (last visited Nov.13, 2009).
4 See id.
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would reimburse for the cost associated with Cerezyme treatment. However, the amount of

reimbursement largely depends on the negotiated rate between the insurance company and the
hospital. 41
In view of the impending health care crisis in the US, CER in the US must first
involve consolidation of all studies, clinical trials, post market surveillance and the like carried out in a therapy area for a specific disease condition. Second, it must apply the result of
the studies to determine the value afforded by various treatment options available in the market. Third, it must weed out treatment options that are not beneficial to the patient population
as a whole. In order to do so, we can use tools such as mathematical modeling, artificial
intelligence algorithms, in addition to the regulatory approval processes.

The United Kingdom and Australia each operate review systems that adopt value
associated with treatments, based on CER. In those countries, comparative effectiveness of
treatments has proven to curtail the overall healthcare spending.4 2 The US has no such consol43
idated and comprehensive review system for medical treatments, drugs or medical devices.
However, the US has the tools needed to integrate the scientific knowledge to the everyday
practice of medicine. The system in the US that minimally resembles the review systems as
adopted by the United Kingdom and Australia is the database of clinical trials maintained by
the NIH. The clinical trial database, however, does not compare the results of distinct clinical
trials of drugs or the relative treatment option in a specific therapy area to determine the
clinical effectiveness or cost effectiveness.44
According to the estimates created for the Commonwealth Fund Commission on a
High Performance Health System, adoption of a CER regimen in the US could potentially
provide a savings of $1.3 trillion in ten years. 45 Moreover, the US does not have a nationalized medical recording system.4 6 In Denmark, a national information exchange repository
contains patients' clinical information. This allows improved decision-making. Such a system
in the US could provide savings of $88 billion in ten years. 4 7 In sum, the American Reinvestment and Recovery Act aims to learn from the CER system of other countries and save costs
associated with the US health care system. 4 8
H.

COMPARATIVE EFFECTIVENESS RESEARCH IN THE UNITED KINGDOM
49

The United Kingdom operates a nationalized health care system.

The government

essentially determines the availability and effectiveness of treatment options through its Na41 See Cerezyme, supra note 40.

42 See Cathy Schoen, supra note 25, at 1753.
43 See Id.
4 See CLINICALTRIALS.Gov, http://clinicaltrials.gov/ (last visited Nov.12, 2009).

45 Cathy Schoen, S. Guterman, A. Shih, J. Lau, S. Kasimow, A. Gauthier, & K. Davis, Bending the Curve:
Options for Achieving Savings and Improving Value in U.S. Health Spending, The Commonwealth Fund pub.

No. 1080, December 2007.
4 See Cathy Schoen supra note 23, at 1753.
47 Id.

48 See The American Recovery and Reinvestment Act of 2009 (ARRA), Pub. L. No. 111-5, 123 Stat. 115,
111th Cong., Ist sess. (2009).
49 David J. Kerr & Mairi Scott, M.B, British Lessons on Health Care Reform, New ENG.J. MED.(Sep. 9, 2009),
available at http://74.125.93.132/search?q=cache:bEVawFdl5YsJ:healthcarereform.nem.org/percent3Fp
percent3D1702+british+lessons+on+health+care+reform&cd=3&hl=en&ct=clnk&gl=us&client=frefox -a (last
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tional Institute of Clinical Excellence (NICE). The philosophy behind this approach is to increase the standard of care by introducing competition and patient choice. This philosophy has
increased the quality of care in the UK where real improvements have been seen in deaths
50
associated with patients suffering from cancer and cardiac problems.
The role of NICE is to provide guidance in public health issues, clinical practice and
new technologies. The objective of the agency is to evaluate the benefits associated with each
5
treatment and determine the cost value of each treatment in relation to the benefits. ' To
achieve this goal, NICE compares different treatments for a specific disease condition by the
use of statistical methods and systematic review processes. 52 The processes are transparent
53
and it involves and encourages participation from the industry, academia and patient groups.
In order to evaluate each proposed treatment under study, NICE calculates the cost

per Quality Adjusted Life Year, also called QALY. The QALY computation is based on a
mathematical model. 54 The model takes input variable measurements based on the effectiveness of the drugs under comparison, the time gained by the treatment, the quality of life
improvement rendered by the treatment, the disease progression and other time scales involved in the process. The rationale behind the cost per QALY evaluation is that a drug that
extends the lifetime of a patient must not be one that makes the patient spend the extended

lifetime in pain. For example, the cost per QALY analysis might analyze whether a month
gained by a cancer treatment can be valued at $1000, $10,000 or $100,000.5s The assessment
team combines the quantity of time a drug might provide to the life span of the patient with
the quality of time. 56 Based on the result, the researchers set a threshold point. At the thresh5 7
old point, the cost associated with the treatment no longer adds value benefit to the patients.
NICE does not support treatment options that have a QALY factor beyond the threshold point.
Once the team determines the QALY factor, the result is returned to the appraisal committee.
The appraisal committee consists of medical practitioners, researchers and lay people. This
committee determines the guidelines for treatment based on the QALY factor. Generally, all
recommendations with a cost per QALY value less than E30,000 are approved. Any recommendation that is higher than the limit of £30,000 is not approved. This type of decisionmaking is not free from debate. 58 Critics argue that the quality of life cannot be determined on
the basis of mathematical terms and such threshold values, particularly in life threatening
diseases, demeans patient population. They claim that the process creates obstacles for patients who are willing to receive the drug, especially those who can afford the cost of the
visited Nov 13, 2009), See generally http://www.nhs.uk/Pages/HomePage.aspx (last visited Nov 13, 2009)
[hereinafter "Kerr"].
50 See Id. ["There have been massive improvements in waiting times for care and in general patient satisfaction

with the NHS, as well as real improvements in outcomes (fewer deaths from cardiac causes and from cancer),
but there has not been a clear correlation between the amount invested and hard health outcomes, and Britain's
Audit Office has raised doubts about the link between productivity and salary increments"].
51See NAT'L INsTYT. OF CLINICAL EXCELLENCE, available at http://www.nice.org.uklaboutnice/howwework/
howweworkjsp (last visited Mar 19, 2010).
52 See id.

"
5
5
56
5
58

See
See
See
See
See
See

id.
Cathy Schoen, supra note 23.
id.
Kerr, supra note 49.
id.
id.
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treatment. 59 On the other hand, the economists argue that such a system is the best available
option in CER research and thereby provides an effective cost benefit analysis of medical
treatments. 60
NICE Systematic Review Of Cetuximab
Cetuximab (brand name Erbitux6 t ) is a chimeric monoclonal antibody that inhibits
intercellular signaling through the Epidermal Growth Factor (EGF) receptor. It is used to treat
metastatic colorectal cancer, as well as head and neck cancer. Cetuximab blocks EGF62 receptors (EGFR), thereby inhibiting the proliferation of cells that depend on EGFR activation for
growth and downstream signaling.6 3
In June 2009, NICE recommended the use of Cetuximab in combination with chemotherapy as a first line of therapy for the treatment of metastatic colorectal cancer.64 The
guidelines required that the patient meet two additional criteria. First, the patient must present
as a potential candidate for curative surgery.65 Second, the cancer should have spread only to
the liver and patient must have a normal, or wild-type, K-ras tumors. 66 In addition, the guidelines specifically mentioned that the patient should continue the treatment for only 16 weeks.
After 16 weeks, the patient is to be evaluated for liver metastasis. 67 These guidelines are
based on two randomized clinical trials submitted by the manufacturer: (1) CRYSTAL (Cetuximab combined with iRinotecan in first line therapY for metaSTatic colorectAL cancer), 68
which is a phase III multicentre randomized clinical trial that compared treatment with Cetux5 See id.
60 Id.

61 See ERByrux, http://www.erbitux.com/ (last visited Nov 13, 2009).
62 See id.
63 See Robert M. James et.al, K -ras Proto -Oncogene Exhibits Tumor Suppressor Activity As Its Absence
Promotes Tumorigenesis in Murine Teratomas, 1 MOLECULAR CANCER RESEARCH 820-825 (Sept. 2003),
available at http://mcr.aacrjournals.org/content/1/1 1/820.full.pdfTml (last visited Nov 30, 2009) ("Ras proteins
transduce signals from membrane -bound receptors via multiple downstream effector pathways and thereby
affect fundamental cellular processes, including proliferation, apoptosis, and differentiation. K-ras activating
mutations play a key role in neoplastic progression and are particularly prevalent in colorectal, pancreatic and
lung cancers"), FDA, Cetuximab (Erbitux) and Panitumumab (Vectibix), available at http://www.fda.gov/
AboutFDA/CentersOffices/CDER/ucml72905.htm (last visited Novl3, 2009).
6 See UK's NICE Recommends Use Of Erbitux ForMetastatic Colorectal Cancer Patients, MEDICAL NEWS
TODAY, June 2., 2009, available at http://www.medicalnewstoday.com/articles/152247.php (last visited Nov 13,
2009).
61 See id.
66 See id. See also Robert M. James et.al, K -ras Proto -Oncogene Exhibits Tumor Suppressor Activity As Its
Absence Promotes Tumorigenesis in Murine Teratomas, 1 MOLECULAR CANCER RESEARCH 820-825
(September 2003), available at http://mcr.aacrjournals.org/content/l/I1/820.full.pdftml

(last visited Nov. 30,

2009) ("Ras proteins transduce signals from membrane -bound receptors via multiple downstream effector
pathways and thereby affect fundamental cellular processes, including proliferation, apoptosis, and
differentiation. K-ras activating mutations play a key role in neoplastic progression and are particularly
prevalent in colorectal, pancreatic and lung cancers").
67 See Cetruximab for the first-line treatment of metastatic colorectalcancer, NICE, Aug. 2009, available at
http://guidance.nice.org.uk/TAl76/Guidance/pdflEnglish (last visited Nov. 13, 2009).
6 See Erbitux (cetuximab) Combined With Chemotherapy Extends Survival From 21 To Nearly 25 Months For
KRAS Wild-Type Metastatic Colorectal Cancer Patients, MEDICAL NEWS TODAY, Sep.19.2008, available at
http://www.medicalnewstoday.com/articles/122165.php

(last visited Nov. 13, 2009) [hereinafter "Cetuximab"].
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imab in combination with Folfiri 69 and treatment with Folfiri alone; and (2) OPUS (OxaliPlatin and cetUximab in firSt-line treatment of mCRC) 70 , a phase II randomized clinical trial,
which compared Cetuximab in combination with Folfox 7l and treatment with Folfox alone 72.
The appraisal committee considered the analysis of clinical effectiveness and cost effectiveness of Cetuximab. In order to assess the accuracy of testing on patients with the K-ras mutation gene73 , , the committee reached out to clinical specialists. The committee was concerned
about the statistically non-significant progression of the survival rate in the two trials. However, they based their assessment on the reassurance of clinical specialists that Cetuximab
played a primary role in shrinking secondary liver metastases and that it enabled curative liver
resection in people with K-ras wild-type metastatic colorectal cancer. In evaluating the costeffectiveness, the QALY factor for Cetuximab in combination with FOLFOX as opposed to
FOLFOX alone was between E26,700 as estimated by the manufacturer and £33,300 as estimated by the Decision Support Unit (DSU) of NICE. 74 This was within the threshold limit
established by NICE and the appraisal committee approved Cetuximab as a first line therapy
for treating metastatic colorectal cancer.7 5
NICE Systematic Review Of Sunitinib
The evaluation of Sunitinib (brand name Sutent) 76 for the treatment of kidney cancer
caused some trouble for NICE. Sunitinib, manufactured by Pfizer, is indicated for the treatment of gastrointestinal stromal cell carcinoma and advanced renal carcinoma.77 Sunitinib
inhibits multiple tyrosine kinases that play a role in tumor growth and cancer metastasis.78
During the initial evaluation, NICE concluded that the price of Sunitinib outweighed its
See

HELP, UK, http://www.cancerhelp.org.uk/ (last visited Nov.13, 2009) [hereinafter "Cancer
Help"]; Cetuximab, supra note 68.
70 See. Cetuximab, supra note 68.
7 See Cancer Help, supra note 69.
72 See Cetuximab, supra note 68.
73 Erbitux With FOLFIRI Or FOLFOX ChemotherapyHelps Advanced Bowel CancerPatients With WT-KRAS
Tumours Live Longer, MEDICAL NEWS TODAY, Sep. 29, 2009, available at http:// www.medicalnewstoday.com/
articles/165577.php (last visited Nov.13, 2009).
7 See THE UNIV. OF SHEFFIELD, http://www.shef.ac.uk/scharr/sections/heds/collaborations/nicedsu.html (last
visited Nov. 13, 2009). "The Decision Support Unit (DSU) is commissioned by The National Institute for
Health and Clinical Excellence (NICE) to provide a research and training resource to support the Institute's
Technology Appraisal Programme. DSU is a collaboration between the Universities of Sheffield (Health
Economics and Decision Science, Centre for Health Economics and Bayesian Statistics, Department of
Probability and Statistics), York (Centre for Health Economics), Leicester (Department of Health Sciences)",
See also Final appraisaldetermination Cetuximab for the first-line treatment of metastatic colorectal cancer,
NAT'L INSTITUTE FOR HEALTH & CLINICAL EXCELLENCE, available at www.nice.org.uk/nicemedia/pdf/
ColorectalCancerCetuximabFAD.pdf(last visited April.15, 2011).
75 See Cancer Help, supra note 72.
76 See Pfizer For Oncology Professionals, PFIZER.COM, available at https://www.pfizeroncology.com/Sutent/
default.aspx (last visited Nov.13, 2009).
7 See A. Dalgleish and J. Copier, New multitargeted treatments with antiangiogenic and antitumor activity:
focus on Sunitinib, 2 TARGETED ONCOLOGY 1776 -2596 (Jan 2007) ("Sunitinib malate, an oral mult -targeted
receptor tyrosine kinase inhibitor, multi - targeted inhibitors Sorafenib, Lapatinib and Dasatinib have
69

CANCER

demonstrated activity against a range of tumor types and show promise in settings for which few (if any)
alternative treatments are available").
78 See SuTENr, PFIZER.COM, available at http://www.pfizer.com/products/rx/rx-product sutent.jsp (last visited

Nov.13, 2009).
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clinical effectiveness and, therefore, did not exhibit value.79 This decision resulted in patient
outcry and physician disapproval of using NICE's system used to evaluate drugs that treat
small patient population affected by rare diseases. The media questioned NICE's evaluation
strategies, particularly the use of a mathematical model. They suggested that mathematical
models are primarily designed to test the clinical effectiveness and cost effectiveness of drugs
in large groups of patients.80 Following the negative response, NICE reevaluated its assessment strategies. The reassessment was in part due to the decision of Pfizer to provide Sunitinib free of cost for the first round of treatment.8 1 In spite of the heavy discount, the drug was
still very expensive. 82 However, NICE claimed that it was "a significant step-change in treating a disease for which there is currently so little to offer patients". This led to the approval of
Sunitinib.8 3
These two case studies on NICE's evaluation strategies elucidates three important
factors about Comparative Effectiveness Research. First, CER is influenced by social, economical and political factors and requires cooperation between patients, physicians, payors,
pharmaceutical and biotech industry and the government agency responsible for the approval
of the drugs. Second, without hard assessment on the value obtained by drugs and the cost
involved, the cost of health care will triple in the next few decades. Therefore, CER is a
necessary mechanism. It is advancement in the right direction that might improve the quality
of health care services and curtail the health care cost. Third, NICE's guidelines are not etched
in stone. The guidelines must be flexible, transparent, adaptable to necessity, patient and physician responses and other ethical concerns.
III. COMPARATIVE EFFECTIVENESS RESEARCH IN THE UNITED STATES
History
Comparative effectiveness research in the US has been in progress for the past two
decades. During 1989, the Agency for HealthCare Policy and Research (AHCPR) 84 established Medical Treatment Effectiveness Program (MEDTEP). The objective of MEDTEP was
to fund research for determining effectiveness of treatments, develop guidelines and other
databases. 85 In 1992, the Congress directed AHCPR to include cost effectiveness and clinical
effectiveness of treatment options in its MEDTEP program. The resulting criticism against the
program led the Congress to decrease the budget of the agency by 20 percent; the MEDTEP
program eventually ended.
79 See Susan Mayor, NICE recommends kidney cancer drug it previously rejected on cost grounds, BMJ.com,
(Feb. 9,2009), available at http://www.bmj.com/cgi/content/extract/338/febO9_2/b499 http://www.bmj.com/cgi/
content/extract/338/feb09_2/b499 (last visited Nov.13, 2009).
s0 Id.

81 See id.
82 See Henry Scowcroft, NICE Recommends Sutent (Sunitinib)for Advanced Kidney Cancer,SCIENCE UPDATE
BLOG (Feb. 4, 2009, 5:50 PM), http://scienceblog.cancerresearchuk.org/2009/02/04/nice -recommends-sutentsunitinib-for-advanced-kidneycancer/ (last visited Nov.13, 2009).
83 Id.

8 Agency of Health care Policy and Research, which was later called as Agency of Health care Research and
Quality (AHQR).
85 See Claire W. Maklan, et. al., Methodological Challenges and Innovations in Patient Outcomes Research,
32 MEDICAL CARE JS13 -JS21 (July 1994).
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In 1999, the agency was renamed as Agency for Health Care Research and Quality.
AHRQ has many centers that carry out health care research. 86 In 1999, the Food and Drug
Administration Modernization Act authorized AHRQ to conduct research on risks, benefits,
cost effectiveness and optimal use of drugs, biologics and medical devices around the nation.
The research was to be performed in conjunction with the FDA, academic institutions and
health care industry.87 The Medicare Prescription Drug, Improvement and Modernization Act
(MMA) 88 of 2003 authorized $50 million for AHRQ to conduct research on clinical effectiveness and outcomes on pharmaceuticals, medical devices and health care services. Based on the
allocation, the agency created programs such as DEcIDE and Evidence based Practice
Center's Program (EPCs) to effectively analyze the cost effectiveness of health care through
technology assessments.89 Since 1985, the Technology assessment Center (TEC) of Blue
Cross Blue Shield had evaluated the relative effectiveness of various treatment options on the
basis of lifetime and quality of life. In 1999, AQHR funded TEC as an Evidence Practice
Center. 90 The Department of Defense (DOD) established Pharmaco Economic Center (PEC)
in 1992 to improve the clinical, economic, and humanistic outcomes of drug therapy in support of the readiness and managed healthcare missions of the Military Health System. 9 1
In addition to AQHR, many non-profit agencies have been involved in CER. One
among them is the Consumer Reports Best Buy Drug Projects, which evaluates the drug
prices and effectiveness of drugs. It provides free report on its website. Similarly, ECRI, a
non-profit organization provides health care and effectiveness assessments. 92 Many for profit
organization also develop clinical effectiveness information to support their decisionmaking. 93

86 See Bradford H. Gray et. al. AHCPR and the Changing Politics of Health Services Research, HEALTH
AFFAIRS W283 -307 (2003).), available at http://content.healthaffairs.org/contentlearly/2003/06/25/hlthaff.w3.
283.full.pdf+html.
8 See AHRQ, supra note 3.
88 Medicare Prescription Drug, Improvement and Modernization Act of 2003 (MMA), Pub. L. No. 108 -173,
§1013., 117 Stat. 2066, 2438.
89 See Mark Helfand, Incorporating Information About Cost -Effectiveness Into Evidence -Based Decision
Making, 7 suppl. II MEDICAL CARE 33, 34-35-43 (July 2005). See also GRETCHEN A. JACONBSON, CONG.
RESEARCH SERV., COMPARATIVE CLINICAL EFFECTIVENESS AND COST EFFECTIVENESS; BACKGROUND,

HISTORY,

AND OVERVIEW (October. 15, 2007).

9 See Health Care: Technology Assessment Subdirectory Page, AHRQ.Gov, available at http://www.ahrq.
gov/clinic/techix.htm (last visited Nov.13, 2009).

91 See Kevin Ridderhoff & Daniel Remund, The Department of Defense Pharmacy Benefit Management
Program, 170 MILITARY MEDICINE 302 (April 2005).

92 See Drug Effectiveness Review Project (DERP), OR. HEALTH & Sa., available at http://www.ohsu.edul
drugeffectiveness/descrip tionlindex.htm (last visited Nov. 13, 2009).
9 See InterQualDecision Report, McKesson, http://www.interqual.com/ IQSite/about/history.aspx (last visited
Nov. 13, 2009).
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OBSTACLES AND POLICY IMPLICATIONS OF CER
IN THE UNITED STATES

Role Of The FDA In Evaluation and Implementation Of CER
Laws regulating drug discovery, development and commercialization began with the
Federal Food and Drug Act of 190694, followed by the Federal Food, Drug and Cosmetic Act
of 1938,95 and the Biologics Control Act of 1902.96 The laws have changed over time with
the evolution of science, technology and medical practice. The recent Food and Drug Administration Amendment Act of 2007 (FDAAA) 9 7 provides the Food and Drug Administration
("FDA") with significant power to regulate safety, post market study and surveillance of
drugs, biologics and medical devices. In light of the need for comparative effectiveness research in the US, the FDA should be provided with the authority to set priorities, to compare
various treatment options and to determine which treatment works best. The FDA has the
scientific and technical expertise to engage in the process of CER.
During the next several decades, CER along with post market approval safety studies
and risk evaluation and mitigation strategies codified in FDAAA 98 may become the source for
the most important advancements in laws regulating the discovery, development and commercialization of drugs, biologics, medical devices and advanced therapies. If carried out correctly, CER has the potential of becoming a repository of knowledge that summarizes and
compares various discrete studies that aim to cure a specific disease. 99 Thereby, it would
enable the payor's, the patients, the policy makers and the practitioners to use the resources in
the most efficient manner.
CER And Industry's Incentive To Innovate
Adoption of CER in the US poses many problems. First, there exists an argument
that CER will undercut the incentive for the life science companies to innovate. The response
to this argument is two-fold. First, if the US invests in and adopts a comprehensive CER for
health care products such as drugs, biologics, medical devices and other advanced therapies,
the regulatory agency responsible for its administration, might require manufacturers to provide information that compares the efficacy, safety and cost effectiveness of their product to
those available in the market. Although the CER regime of this sort would press the health
care industry to expand the scope and size of clinical trials and add the costs associated with
conducting clinical and regulatory development, it will force each participant in the industry
to evaluate its pricing and drug development strategies.'" The cost and complexity of complying with such a regime of CER could mean fewer new molecular entities will be discov94
9
9
9
98
9

Federal Food, Drug and Cosmetic Act of 1902, 21 USC§ 1. (repealed 1938).
Federal Food, Drug and Cosmetic Act of 1938, 21 USC § 301.
Biologics Control Act, Pub. L. No. 57-244, 32 U.S. Stat 728 (July 1, 1902).
Food and Drug Administration Amendments Act, 21 USC § 301 [hereinafter "FDAAA"].
Id.
Lynn M. Etheredge, Creating A High-PerformanceSystem For Comparative Effectiveness Research, 29
HEALTH AFFAIRS, no. 10, 1761 (2010).
'" Avalere Explores Impact of Comparative Effectiveness Research on Healthcare Innovation, AVALERE .NET
(Nov. 17, 2009), http://www.avalerehealth.net/wm/show.phpc=1 (last visited on Nov. 31, 2009) [hereinafter
"Avalere"].
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ered and developed as early stage pipeline candidates, fewer surviving to the late stage
pipeline. In a CER regime of this sort, industry participants will have to live by the paradigm:
"survival of the fittest". 10 1 On one hand, it will result in the availability of more capital
investment to explore areas and technologies that have not yet been explored. The industry
will have fewer incentives to discover and develop a "me too drug or device". Instead, the
industry will channel the available resources to explore new areas of sciences and narrowly
defined markets that hold therapeutic and commercial potential 10 2 such as personalized
medicine and nanomedicine. 103 On the other hand, the FDA, will have to engage in the approval process of drugs which otherwise would not be approved by FDA due to the lack of
guidelines or the frame work that is required for the approval process.
We live in an era where gene matrixes and mRNA analysis are effectively used to
decode the DNA of a disease-causing gene.'0 Without effective CER regulations and implementation, such groundbreaking technologies will not be effectively used to provide cost effective medical options. Instead, they might end up as one of the many means of achieving an
effective medical treatment. 105 This is a double-edged sword for both the industry and the
FDA. Participants of the industry would have to differentiate themselves from the others in
their discovery, development and commercialization efforts, whilst the FDA must endeavor to
approve drugs that hold promise in narrower therapeutic areas. The drugs that are approved
under such regulations might hold greater promise for the cost effective and clinically effective treatment of diseases. 1 06
Healthcare In The US
The US health care system is dissimilar to that of the UK. The US healthcare system
reflects the American way of life. Therefore, there exist serious doubts whether adopting a
threshold cost per QALY factor similar to that of UK is possible in the US. Adopting a regime
that determines the availability of a drug or treatment based on mathematical models and
systematic evaluation strategies might give rise to ethical concerns in the practice of medicine
as well as drug discovery and development efforts. 1 07 Moreover, it can also be argued that the
US Constitution affords right for health care; any effort to limit an individual's access to
medicine violates his or her constitutional rights. These arguments require an in depth analysis
of constitutional and ethical concerns associated with CER and, thus are beyond the scope of

101Valerie Fleishman, Balancing Act: CER and Innovation in U.S. Health Care, New England Health Care
Institute, Sept. 17, 2009), www.ehcca.com/presentations/compeffectivel/fleishman_2.pdf (last visited Nov. 31,
2009).
102 Alvin Mushlin & Hassan Ghomrawi, Health Care Reform and the Need for Comparative Effectiveness
Research, 362 NEw ENG.J. MED.e6(2) [hereinafter Mushlin & Hassan"].
103 Robert Epstein &J. Russell Teagarden, Comparative Effectiveness And Personalized Medicine: Evolving
Together Or Apart?, 29 HEALTH AFFAIRS, no. 10, 1783 (2010).
'0 See id.
105 See Mushlin & Ghomrawi, supra note 102, at e6(l).
106 21 Century Science: Comparative Effectiveness Research and Personalized Medicine, NAT'L
PHARMACEUTICAL COUNCIL, http://www.regonline.com/custImages/253701/CERpercent20andpercent2OPM
percent20Issuepercent20Brief.pdf (last visited Mar. 3, 2011) .

107 Somnath Saha, et. al., Giving Teeth to Comparative Effectiveness Research-The Oregon Experience, 362
NEw ENG.J. MED., Feb. 18, 2010, at e18.
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this note. 0 8 Considering the impact of health care spending on the US economy, the theme
that emerges is the US must adopt a CER regime of some sort that effectively determines the
value afforded by different medical options and restricts those options that provide lesser or
no value benefit to the patients. For example, inexpensive diuretic medications are shown to
prevent heart attacks more effectively in Prevent Heart Attack Trial (ALLHAT) than expensive angiotensin converting enzyme inhibitors, calcium channel blockers, and alphablockers. 109
User Redefined
In the context of CER, the concept of the "user" of products as discussed by the
commentators seems to be an evolving concept. In 1963, the US District Court for the District
of Columbia in Stottlemire v. Cawood and Parke Davis Company held that prescription drugs

0
do not necessarily require that warnings be directed towards the general public. " In 1969,
the US Court of Appeals for the Eighth Circuit in Sterling Drug Inc. v. Yarrow held that "the
manufacturer could be held liable for the injury resulting from the failure to give a warning
reasonable under the circumstances".I
In both these cases the Court relied on the learned intermediary doctrine to determine that physicians comprise the target audience or end user for the purposes of determining
the appropriateness of the respective labeling. 1'2 In 1985, in MacDonald v. Ortho Pharmaceutical Corporation,the Massachusetts Supreme Judicial Court held that the manufacturer of
birth control pills owe a direct duty to warn the patient about the risks involved with the
1 14
In
drug." 3 The Court defined the target audience for labeling information as the patients.

1980, in PharmaceuticalManufacturers v. Food and Drug Administration, the Court of Ap-

peals for the Third Circuit held that under the provisions of Federal Food, Drug and Cosmetic
Act of 1938, "the FDA was within its statutory authority to require patient package inserts
where it found that without the insert, the estrogen labeling failed to reveal facts of consequences resulting from the use of the drug".
These cases demonstrate the evolution of laws, which defines the "user" of the information provided by the drug manufacturers. The concept of CER prompts the question, who is
the "intended user" of the CER information? The critics argue that the concept of CER is
analogous to defining the "payor" as the intended user. They claim that since the information
obtained through CER will help payors in their decision making process, CER effectively
ignores the patient and physician classes and provides commercial empowerment to the payor
class.
1os Ethical issues could be averted by drafing policies that involve academia, industry and practitioners in the
assessment processes and by making the decision-making more transparent. The question whether CER violates
individual's constitutional rights is a subject for another article.
'0 Andrew Pollack, The Evidence Gap: The Minimal Impact of a Big Hypertension Study, N.Y. TimES, Nov.
28, 2008) at Bl.
110 See Stottlemire v. Cawood, 213 F. Supp. 897, 898 (D.D.Cir 1963).
"I See Sterling Drug, Inc. v. Yarrow, 408 F.2d 978, 993 (8th Cir. 1969).
112 Id.at 99.

113 MacDonald v. Ortho Pharmaceutical Corp., 394 Mass. 131, 139 (Mass. 1985).
114 Id.
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V. PROPOSED PLANS FOR IMPLEMENTATION OF CER
IN THE UNITED STATES
This section proposes a three level plan for implementing CER in the US.
Physicians - The Implementors Of CER
Key to any successful legislation is the proper implementation at the most basic
level. In CER, the basic implementors are the physicians. It is the physician who decides
which drug to prescribe to the patient. In consultation, with the patients, they determine the
cost associated with medical care. Any cost effectiveness analysis must directly address the
physicians.i 15 One of the factors behind the success of the UK's health care system is the
strength of the primary care practice in the UK. The primary care physicians in the UK focus
on the health of the patient as a whole rather than on one particular organ. They tend to use the
help of specialty practice only when they really need it. 116 In the US, the practice of medicine
has a gross deficit of general practitioners of medicine. Meanwhile, specialty practitioners of
medicine are increasing at a steady rate. 17 The main reasons for this discrepancy are the
expensive technologies that are being used and the pay-for-performance feature in the practice
of medicine.I"s Consequently, the specialty practice has the incentive to use expensive tests in
lieu of the cost effective tests. Therefore, a regulation that curtails the cost of the procedure or
bases the fees on the outcome of the procedure will not remedy the problem. This is because
the amount charged for the procedures are completely at the will of the physicians and they
control the volume at large. Therefore, one of the proposed solutions is limiting the pay-forperformance programs and turning the focus towards the practice of primary care medicine.
The United Kingdom's Audit Office raised doubts about the link between the productivity and the salary increments of physicians in the UK when they found discrepancies
behind the amount spent on health care reform and statistics on hard-health outcomes.119
Similarly, in the US, the pay of the physician correlates to the amount of expensive procedures prescribed and the volume at large. Such practices of medicine and payment methods
affect the affordability of the society as a whole. The pay-for-performance system must be set
such that it provides incentives for the physicians for providing higher quality care in a cost
effective manner. 120
Expensive Health Care verses Quality Health Care
There must be a basic shift in the public notion regarding entitlement to expensive
health care in the US. In general, the US economy cannot afford to make expensive procedures available to each patient into boundless future. It is imperative to find the balance between expensive health care for all and value based health care for all. This requires answers
115 Arnold Relman, Doctors as the key to health care reform, 361 NEw ENGJ. MED. 13, (Sept. 24, 2009),
available at http://healthcarereform.nejm.org/?p=1884 [hereinafter "Relman"].
116 See The American Recovery and Reinvestment Act of 2009 (ARRA), Pub. L. No. 111-5, 11Ith (2009).
117 See Relman, supra note 115.
118 Id.
119 See Kerr, supra note 49.

120 See AVALERE, supra, note 100.
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to hard questions such as, is it cost effective and is it beneficial to have patients in the emergency room for simple diagnostic treatments that could be remedied at home? When does
having a patient in a hospital bed provide value for the system in terms of cost of the bed,
labor and other resources? Such regulation requires public involvement, education and public
support. Physicians could be given the responsibility of explaining to the patients when they
should be in a hospital bed and what other treatments could be practiced at home or at lower
cost. This represents a need for shift in public's notion about health care in general and the
need for more focus on general practice of medicine.121
Prevention Better Than Cure
Practice of medicine in the US is largely defensive in nature. The medical practitioners fear malpractice suits. Therefore, they are pressed to prescribe tests, which determine that
the patient is not suffering from a specific disease condition, rather than prescribing tests that
determine whether the patient is suffering from a said disease condition. This is one of the
reasons why specialty practitioners thrive in the US, unlike in the UK.1 22 In spite of billions
of dollars spent on health care each year, the patient population in the US is, on average,
sicker than in many other countries. The US is ranked 54 -55 in the health care around the
world.

23

One of the methods of implementing CER is by practicing preventive medicine.

About 7.8 percent of the US population suffers from diabetes. This amounts to approximately
23.6 million children and adults in the US. Every year an additional 1.6 million people under
the age of 20 are diagnosed with type II diabetes.' 24 The cost associated with treating diabetes
is $174 billion. 125 However, type II diabetes, to an extent, is a preventable disease. Life style
interventions such as proper diet, exercise and weight management can effectively prevent or
control the disease in an efficient manner.
Similarly, vaccinations are an important source of preventive medicine for both children and adults. According to Center for Disease Control, pneumonia and influenza are fifth
leading cause of death in the US, primarily for adults greater than 65 years of age. This figure
has great impact on the health care cost in the US.1 26
Obesity is another therapy area that could be effectively prevented or controlled by
life style interventions. The US spends more than $47 billion combating obesity each year.' 27
The factors needed for practicing preventive medicine are public education and strict regulations. Healthy diet for children, regulation on industry that markets sugar drinks, regulations
on smoking, publishing caloric value of meals are few of the possible efforts that can enhance
121 See Ann C. Bonham and Mildred Z. Solomon, Moving ComparativeEffectiveness Research Into Practice:
Implementation Science And The Role Of Academic Medicine, 29 HEALTH AFFAIRS, no. 10, 1901 (2010).
122See Kerr, supra note 49.
123 See World Health OrganizationAssesses the World's Health Systems, WORLD HEALTH ORG., availableat

http://www.who.int/whr/2000/mediacentre/press-release/en/index.html (last visited Nov.13, 2009).
124 See Diabetes Statistics, AMERICAN DIABETES Assoc., availableat http://www.diabetes.org/diabetes-basics/

diabetes-statistics/(last visited Nov.13, 2009).
125 Id.
126See Thomas Shima, Adult Vaccinations: Practicing Preventive Medicine In The Family Physician's
Office,http://www.acofp.org /resources/publications/archives/0509/0509_2.html (last visited Nov. 7, 2009).
127 See CENTERS FOR DISEASE CONTROL AND PREVENTION, http://www.cdc.gov/obesity/causes/economics.htmi

(last visited Nov. 7, 2009).
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the practice of preventive medicine. 128 The practice of preventive medicine must begin in
medical schools. Aspiring medical practitioners must be able to provide the best treatments for
the patients at a cost effective manner without the fear of litigation.1 29
Methods of implementing CER are not simple. It requires a delicate balance between
the American ways of life; incentive to innovate in pharmaceutical industry and effective
regulatory or statutory guidelines that provide cost effective and clinically effective treatment
options that are affordable to the entire society.1 30
VI.

RECENT DEVELOPMENTS

In June 2009, Institute of Medicine ("IOM") and the Federal Council for Coordinating Comparative Effectiveness Research issued reports on priority topics and future research
engagements for the purpose of implementation of CER. 13 1 The Federal Coordinating Council's report to the President and the Congress identified prioritization criteria for conducting
CER. Among the reported criterion are identifications of subgroups and priority populations
which include: women, minorities, individuals with disabilities, children, people with multiple
conditions and elderly population. The report stressed that the aforementioned priority groups
should be studied in an effort to reduce the economic burden they exert on the US health care
system, and to adequately represent such health conditions in the various research mechanisms. 132 The report also set a long-term operation of CER, which involves continuous analysis of the CER instrument, determining the gaps that exist in the CER instrument and setting
priorities accordingly. Additionally, the Patient Health Patient Protection and Affordable Care
Act of 2010 provided funding for CER through 20 19 .i33 This act sets priorities and established research agendas to the stakeholders of CER.
Tracking The Federal Spending on CER
Based on publicly available information concerning disbursement of American Reinvestment and Recovery Act funds for CER, as of August 4, 2010, $700 million has been
provided to AHRQ and $400 million has been provided to Office of Secretary of Health and
Human services. 13 4 Out of the $700 million allocated to AHRQ, $400 million has been provided to NIH. 13 5 As of August 4, 2010, 82.8 percent of $1.1 billion from ARRA has been
accounted for. 1 36 Out of the 82.8percent, just less than 46.4 percent has been used for activi128 Ari Hoffman et. al., How Best To Engage Patients, Doctors, And Other Stakeholders In Designing
Comparative Effectiveness Studies, 29 HEALTH AFFAIRS, 29,no. 10, 1834 ( 2010).
129 Id.
130 Id.
131 CoM.

ON CoMPARATiVE EFFECrIvENEss RESEARCH PRIORITIZATION, INST. OF MED. INITIAL NATIONAL
FOR
COMPARATIvE EFFECnvENEss RESEARCH. (National Academies Press; 2009).
PRIORITIES
132 US DEIPT. OF Health & HUMAN SERv., FEDERAL COORDINATING COUNCIL FOR COMPARATIVE
EFFEcCTIvENEss RESEARCH, REPORT TO THE PRESIDENT AND THE CONGRESS, (2009).

133 Patient Protection and Affordable Care Act, Pub. L. No. I 11-148, 124 Stat. 1l9 (2010).

13 Joshua S. Benner et. al., An Evaluation Of Recent Federal Spending On Comparative Effectiveness
Research: Priorities,Gaps, And Next Steps, 29 HEALTH AFFAIRS, no.10, 1768 (2010) [hereinafter "Benner"].
135 Id.; see also NIH Research Portfolio Online Reporting Tools (RePORT): RePORT expenditures and results
(RePORTER) NAT'L INSTIT. OF HEALTH; available at http://projectreporter.nih.gov.ezproxy.hofstra.edu/
reporter.cfm.

136 Id.
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ties involving evidence development and synthesis,' 3 7 41.3 percent has been allocated for
research through data, method and infrastructure development, 7.4 percent has been allocated
for developing tools to disseminate evidence to stakeholders, 3.9 percent has been allocated
for priority setting and 1.1 percent has been allocated for activities to engage the stakeholders
of CER.' 3 8
Evidence development and synthesis involves collection of evidences through various methods and development of models to synthesize collected evidences on a given therapeutic area. The entity involved in granting the funding for evidence development and
synthesis is the NIH.1 39 Infrastructure development involves developing methods to analyze
data obtained through routine observational studies in patients and aims to study the cost,
safety and effectiveness of treatments. 140 The granting entity for development of methods and
infrastructure is the Office of Secretary, Health and Human Services.141 Dissemination of
evidence to different stakeholders of CER involves developing various methods for affording
availability of CER data to payors, physicians, patients and policy makers.14 2 The entity involved in granting the funding for dissemination of evidence is the Office of Secretary, Health
and Human Services.143 Stakeholder engagement involves development of citizen's forum for
obtaining public input, development of horizon scanning systems to identify areas for future
research and medical interventions. " The entity involved in granting the funding for dissemination of evidence is the AHRQ. 14
NIH has funded 165 grants totaling $200 million for conducting CER research. The
funds were awarded from the $400 million that was allocated for NIH under American Reinvestment and Recovery Act. Out of $200 million, 21 percent of the funding focused on oncology and hematology, 19 percent cardiovascular and peripheral vascular diseases and 15
percent to psychiatric diseases.' 46 Of the top 10 grants by dollar value, one grant was
awarded to pharmaceutical company and the rest of the grants were awarded to academic
institutions. 147
Further improvement in CER should focus on identification of experimental and
quasi-experimental data for different therapeutic areas of interest, developing strategies to
include understudied populations such as the disabled, rare conditions, development of a national clearing house to evaluate data collected via CER, dissemination of the available evidence to the stakeholders and encouraging use of the research data collected through CER
systems. 148
Id.
Id.
139 Id.
140 Id
141 Id.
142 Id.
1
138

143 Id.
144 Id.

Id.
See Lindsey Spindle, Follow the Comparative Effectiveness Research Dollar:Avalere Finds NIH Focused
on Costly Conditions, Healthcare Costs,, AVALERE (Mar. 9, 2010), http://www.avalerehealth.net/wm/
show.php?c=&id=846 (last visited October 9, 2010).
14
1

147 Id.

148 See Benner, supra note 134.
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Information gathered by the various federal grants awarded by NIH and AHRQ for
CER research must be captured and made available in real-time. Absent a mechanism to
capture and analyze the data, it would be difficult to analyze and compare the effect of infor14 9
Such comparison will
mation obtained from various CER grants on our national priorities.
elucidate the strength and limitations of the database, its usefulness to the public and the CER
as a whole. As of writing of this article, there is insufficient information to perform a comparative review between the information gathered under the federal grants for the purpose of
CER and the national priorities. This is primarily due to the lack of infrastructure in reporting
150
and recording of the information gathered by CER grants.
CONCLUSION
Implementing CER in the US needs support along the social, political and economic
fronts. It will need collaboration from industry, public, physicians and legislators. In spite of
the discrepancies surrounding regulations of CER, the need for CER and the rationale cannot
be rebutted. It is time to overhaul the drug discovery and commercialization laws once again
through effective CER regulations. The goal of attaining cost effective and value based health
care system is not going to be realized immediately. It is an investment for the future in the
right direction. The fruits of our labors by establishing and implementing CER regulations
will be felt in future decades and by next generation of Americans. Curtailing cost of the
health care system today, although rigorous, will be a positive step for our future generations.

149 Id.
150

Id.
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